Literature DB >> 8479744

Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells.

Z Z Su1, V N Austin, S G Zimmer, P B Fisher.   

Abstract

Carcinogenesis requires a complex series of genetic changes often involving multiple oncogenes and the inactivation of multiple tumor-suppressor genes. We presently examined the effect of the Krev-1 tumor-suppressor gene on the tumorigenic and metastatic potential of Ha-ras-transformed cloned rat embryo fibroblast (CREF) cells. Ha-ras-transformed CREF cells are morphologically transformed and anchorage independent; produce reduced levels of nm23-H1 (a putative metastasis-suppressor gene product) and TIMP-1 (tissue inhibitor of metalloproteinase 1) transcripts and mRNA compared with CREF cells; produce increased levels of cripto, 94-kDa gelatinase/type IV collagenase (94-kDa GEL), osteopontin (OPN) and transin/stromelysin transcripts and mRNA compared with CREF cells; and are tumorigenic and metastatic in both nude mice and syngeneic rats. Ha-ras-transformed CREF cells coexpressing the Krev-1 gene display a reversion in cellular phenotype and gene expression to that of untransformed CREF cells. However, Ha-ras/Krev-1-coexpressing CREF cells retain, albeit with extended latency periods, both tumorigenic and metastatic potential that is not related directly to the final level of Ha-ras or Krev-1 mRNA or the Ha-ras p21 transforming protein. Development of metastatic potential is, however, directly correlated with a reduction in nm23-H1 and TIMP-1 transcription and mRNA levels and an enhanced expression of cripto, 94-kDa GEL, osteopontin and transin. In contrast, expression of additional tumor-suppressor genes, such as the RB gene and p53, or genes associated with tumorigenesis in other model systems, such as major excreted glycoprotein (MEP), 72-kDa gelatinase/type IV collagenase (72-kDa GEL), fibronectin (FIB), tenascin and intracellular adhesion molecule 1 (ICAM-1) is not altered in a consistent manner during in vitro transformation suppression or escape from tumorigenic and metastatic suppression. These results indicate that Krev-1 suppression of the Ha-ras-transformed/oncogenic phenotype is associated with a distinct program of gene expression changes manifested by altered rates of transcription and steady-state mRNA levels of specific oncogenic-suppressing and oncogenic-inducing genes. These data support a model of Ha-ras-induced metastasis in CREF cells that involves a direct modulation in the expression/suppression of specific combinations of oncogenic-suppressor genes and metastasis-promoting genes that are regulated coordinately in the process of tumor progression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8479744

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  Detachment of transformed cells. Role of CD44 variants.

Authors:  C Santos; K Chandler; S Zimmer; P B Fisher; U Gunthert; K W Anderson
Journal:  Cell Biophys       Date:  1995-02

2.  Osteopontin overexpression in vascular smooth muscle cells transfected with the c-Ha-rasEJ oncogene.

Authors:  A R Parrish; T J Weber; K S Ramos
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-09       Impact factor: 2.416

3.  Antisense inhibition of the PTI-1 oncogene reverses cancer phenotypes.

Authors:  Z Su; N I Goldstein; P B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

4.  PEG-3, a nontransforming cancer progression gene, is a positive regulator of cancer aggressiveness and angiogenesis.

Authors:  Z Z Su; N I Goldstein; H Jiang; M N Wang; G J Duigou; C S Young; P B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

5.  PEA3 sites within the progression elevated gene-3 (PEG-3) promoter and mitogen-activated protein kinase contribute to differential PEG-3 expression in Ha-ras and v-raf oncogene transformed rat embryo cells.

Authors:  Z Su; Y Shi; R Friedman; L Qiao; R McKinstry; D Hinman; P Dent; P B Fisher
Journal:  Nucleic Acids Res       Date:  2001-04-15       Impact factor: 16.971

6.  Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display.

Authors:  R Shen; Z Z Su; C A Olsson; P B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

Review 7.  Tumor suppressor genes and their roles in breast cancer.

Authors:  L A Cox; G Chen; E Y Lee
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

8.  Immunohistochemical expression of osteopontin in gastric cancer.

Authors:  Motohiro Imano; Takao Satou; Tatsuki Itoh; Kenichi Sakai; Eizaburo Ishimaru; Atsushi Yasuda; Ying-Feng Peng; Masayuki Shinkai; Fumiharu Akai; Takushi Yasuda; Haruhiko Imamoto; Kiyokata Okuno; Hiroyuki Ito; Hitoshi Shiozaki; Harumasa Ohyanagi
Journal:  J Gastrointest Surg       Date:  2009-07-07       Impact factor: 3.452

Review 9.  Selected approaches for rational drug design and high throughput screening to identify anti-cancer molecules.

Authors:  Michael Hedvat; Luni Emdad; Swadesh K Das; Keetae Kim; Santanu Dasgupta; Shibu Thomas; Bin Hu; Shan Zhu; Rupesh Dash; Bridget A Quinn; Regina A Oyesanya; Timothy P Kegelman; Upneet K Sokhi; Siddik Sarkar; Eda Erdogan; Mitchell E Menezes; Praveen Bhoopathi; Xiang-Yang Wang; Martin G Pomper; Jun Wei; Bainan Wu; John L Stebbins; Paul W Diaz; John C Reed; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher
Journal:  Anticancer Agents Med Chem       Date:  2012-11       Impact factor: 2.505

10.  Subtraction hybridization identifies a transformation progression-associated gene PEG-3 with sequence homology to a growth arrest and DNA damage-inducible gene.

Authors:  Z Z Su; Y Shi; P B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.